Expert Outlook: Fate Therapeutics Through The Eyes Of 9 Analysts
Across the recent three months, 9 analysts have shared their insights on Fate Therapeutics (NASDAQ:FATE), expressing a variety…
Analyst Expectations For Oracle’s Future
During the last three months, 17 analysts shared their evaluations of Oracle (NYSE:ORCL), revealing diverse outlooks from bullish…
Critical Insights From Essex Property Trust Analyst Ratings: What You Need To Know
In the latest quarter, 15 analysts provided ratings for Essex Property Trust (NYSE:ESS), showcasing a mix of bullish…
A Glimpse Into The Expert Outlook On First Interstate BancSys Through 6 Analysts
6 analysts have shared their evaluations of First Interstate BancSys (NASDAQ:FIBK) during the recent three months, expressing a…
6 Analysts Have This To Say About Corcept Therapeutics
During the last three months, 6 analysts shared their evaluations of Corcept Therapeutics (NASDAQ:CORT), revealing diverse outlooks from…
21 Analysts Assess Shake Shack: What You Need To Know
Ratings for Shake Shack (NYSE:SHAK) were provided by 21 analysts in the past three months, showcasing a mix…
A Glimpse Into The Expert Outlook On Cheniere Energy Through 5 Analysts
Cheniere Energy (NYSE:LNG) has been analyzed by 5 analysts in the last three months, revealing a diverse range…
What’s Going On With Palantir’s Stock?
Palantir Technologies shares are trading higher Monday after Argus Research analyst Joseph Bonner initiated coverage on Palantir with a Buy rating and announced a price target of $29. Here's a look at the analyst's note:
Analyst Scoreboard: 4 Ratings For REX American Resources
Ratings for REX American Resources (NYSE:REX) were provided by 4 analysts in the past three months, showcasing a…
Key Takeaways From Zeta Global Holdings Analyst Ratings
During the last three months, 15 analysts shared their evaluations of Zeta Global Holdings (NYSE:ZETA), revealing diverse outlooks…